ID   MK15_HUMAN              Reviewed;         544 AA.
AC   Q8TD08; Q2TCF9; Q8N362;
DT   18-APR-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 1.
DT   12-OCT-2022, entry version 162.
DE   RecName: Full=Mitogen-activated protein kinase 15 {ECO:0000305};
DE            Short=MAP kinase 15;
DE            Short=MAPK 15;
DE            EC=2.7.11.24;
DE   AltName: Full=Extracellular signal-regulated kinase 7;
DE            Short=ERK-7;
DE   AltName: Full=Extracellular signal-regulated kinase 8;
DE            Short=ERK-8;
GN   Name=MAPK15 {ECO:0000312|HGNC:HGNC:24667};
GN   Synonyms=ERK7 {ECO:0000250|UniProtKB:Q9Z2A6}, ERK8
GN   {ECO:0000303|PubMed:11875070, ECO:0000303|PubMed:16484222};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, INTERACTION
RP   WITH CSK, MUTAGENESIS OF LYS-42; THR-175 AND TYR-177, PHOSPHORYLATION AT
RP   THR-175 AND TYR-177, CHARACTERIZATION, FUNCTION, AND ACTIVITY REGULATION.
RC   TISSUE=Testis;
RX   PubMed=11875070; DOI=10.1074/jbc.m112483200;
RA   Abe M.K., Saelzler M.P., Espinosa R. III, Kahle K.T., Hershenson M.B.,
RA   Le Beau M.M., Rosner M.R.;
RT   "ERK8, a new member of the mitogen-activated protein kinase family.";
RL   J. Biol. Chem. 277:16733-16743(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, FUNCTION, AND
RP   INTERACTION WITH ABL1 AND RET.
RC   TISSUE=Medulla oblongata;
RX   PubMed=16484222; DOI=10.1074/jbc.m513397200;
RA   Iavarone C., Acunzo M., Carlomagno F., Catania A., Melillo R.M.,
RA   Carlomagno S.M., Santoro M., Chiariello M.;
RT   "Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3,
RT   a constitutively active form of the RET proto-oncogene.";
RL   J. Biol. Chem. 281:10567-10576(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=16624805; DOI=10.1074/jbc.m512418200;
RA   Saelzler M.P., Spackman C.C., Liu Y., Martinez L.C., Harris J.P., Abe M.K.;
RT   "ERK8 down-regulates transactivation of the glucocorticoid receptor through
RT   Hic-5.";
RL   J. Biol. Chem. 281:16821-16832(2006).
RN   [5]
RP   FUNCTION, PHOSPHORYLATION AT THR-175 AND TYR-177, MUTAGENESIS OF LYS-42;
RP   ASP-155; THR-175 AND TYR-177, AND ACTIVITY REGULATION.
RX   PubMed=16336213; DOI=10.1042/bj20051288;
RA   Klevernic I.V., Stafford M.J., Morrice N., Peggie M., Morton S., Cohen P.;
RT   "Characterization of the reversible phosphorylation and activation of
RT   ERK8.";
RL   Biochem. J. 394:365-373(2006).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [7]
RP   PHOSPHORYLATION AT THR-175 AND TYR-177, FUNCTION, MUTAGENESIS OF ASP-155,
RP   UBIQUITINATION, AND ACTIVITY REGULATION.
RX   PubMed=19166846; DOI=10.1016/j.febslet.2009.01.011;
RA   Klevernic I.V., Martin N.M., Cohen P.;
RT   "Regulation of the activity and expression of ERK8 by DNA damage.";
RL   FEBS Lett. 583:680-684(2009).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20638370; DOI=10.1016/j.bbrc.2010.07.029;
RA   Erster O., Seger R., Liscovitch M.;
RT   "Ligand interaction scan (LIScan) in the study of ERK8.";
RL   Biochem. Biophys. Res. Commun. 399:37-41(2010).
RN   [9]
RP   INTERACTION WITH PCNA, FUNCTION, AND MUTAGENESIS OF GLN-300; PRO-390 AND
RP   PRO-398.
RX   PubMed=20733054; DOI=10.1083/jcb.201002124;
RA   Groehler A.L., Lannigan D.A.;
RT   "A chromatin-bound kinase, ERK8, protects genomic integrity by inhibiting
RT   HDM2-mediated degradation of the DNA clamp PCNA.";
RL   J. Cell Biol. 190:575-586(2010).
RN   [10]
RP   FUNCTION.
RX   PubMed=21847093; DOI=10.1038/emboj.2011.253;
RA   Zacharogianni M., Kondylis V., Tang Y., Farhan H., Xanthakis D., Fuchs F.,
RA   Boutros M., Rabouille C.;
RT   "ERK7 is a negative regulator of protein secretion in response to amino-
RT   acid starvation by modulating Sec16 membrane association.";
RL   EMBO J. 30:3684-3700(2011).
RN   [11]
RP   INTERACTION WITH ESRRA, SUBCELLULAR LOCATION, MUTAGENESIS OF
RP   265-LEU--LEU-269 AND 281-LEU--LEU-285, REGION, AND FUNCTION.
RX   PubMed=21190936; DOI=10.1074/jbc.m110.179523;
RA   Rossi M., Colecchia D., Iavarone C., Strambi A., Piccioni F.,
RA   Verrotti di Pianella A., Chiariello M.;
RT   "Extracellular signal-regulated kinase 8 (ERK8) controls estrogen-related
RT   receptor alpha (ERRalpha) cellular localization and inhibits its
RT   transcriptional activity.";
RL   J. Biol. Chem. 286:8507-8522(2011).
RN   [12]
RP   INTERACTION WITH GABARAP; MAP1LC3B AND GABARAPL1, SUBCELLULAR LOCATION,
RP   REGION, MUTAGENESIS OF ASP-155 AND 340-TYR--ILE-343, AND FUNCTION.
RX   PubMed=22948227; DOI=10.4161/auto.21857;
RA   Colecchia D., Strambi A., Sanzone S., Iavarone C., Rossi M., Dall'Armi C.,
RA   Piccioni F., Verrotti di Pianella A., Chiariello M.;
RT   "MAPK15/ERK8 stimulates autophagy by interacting with LC3 and GABARAP
RT   proteins.";
RL   Autophagy 8:1724-1740(2012).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-175 AND TYR-177.
RX   PubMed=24618899; DOI=10.7554/elife.01828;
RA   Chia J., Tham K.M., Gill D.J., Bard-Chapeau E.A., Bard F.A.;
RT   "ERK8 is a negative regulator of O-GalNAc glycosylation and cell
RT   migration.";
RL   Elife 3:E01828-E01828(2014).
RN   [14]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-449, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [15]
RP   FUNCTION.
RX   PubMed=26595526; DOI=10.18632/oncotarget.6363;
RA   Liwak-Muir U., Dobson C.C., Naing T., Wylie Q., Chehade L., Baird S.D.,
RA   Chakraborty P.K., Holcik M.;
RT   "ERK8 is a novel HuR kinase that regulates tumour suppressor PDCD4 through
RT   a miR-21 dependent mechanism.";
RL   Oncotarget 7:1439-1450(2016).
RN   [16]
RP   SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS OF LYS-42.
RX   PubMed=29021280; DOI=10.1534/genetics.117.300383;
RA   Kazatskaya A., Kuhns S., Lambacher N.J., Kennedy J.E., Brear A.G.,
RA   McManus G.J., Sengupta P., Blacque O.E.;
RT   "Primary Cilium Formation and Ciliary Protein Trafficking Is Regulated by
RT   the Atypical MAP Kinase MAPK15 in Caenorhabditis elegans and Human Cells.";
RL   Genetics 207:1423-1440(2017).
RN   [17]
RP   FUNCTION, AND MUTAGENESIS OF LYS-42 AND ARG-59.
RX   PubMed=28842414; DOI=10.1523/jneurosci.1582-17.2017;
RA   Bermingham D.P., Hardaway J.A., Refai O., Marks C.R., Snider S.L.,
RA   Sturgeon S.M., Spencer W.C., Colbran R.J., Miller D.M. III, Blakely R.D.;
RT   "The Atypical MAP Kinase SWIP-13/ERK8 Regulates Dopamine Transporters
RT   through a Rho-Dependent Mechanism.";
RL   J. Neurosci. 37:9288-9304(2017).
CC   -!- FUNCTION: Atypical MAPK protein that regulates several process such as
CC       autophagy, ciliogenesis, protein trafficking/secretion and genome
CC       integrity, in a kinase activity-dependent manner (PubMed:22948227,
CC       PubMed:24618899, PubMed:29021280, PubMed:21847093, PubMed:20733054).
CC       Controls both, basal and starvation-induced autophagy throught its
CC       interaction with GABARAP, MAP1LC3B and GABARAPL1 leading to
CC       autophagosome formation, SQSTM1 degradation and reduced MAP1LC3B
CC       inhibitory phosphorylation (PubMed:22948227). Regulates primary cilium
CC       formation and the localization of ciliary proteins involved in cilium
CC       structure, transport, and signaling (PubMed:29021280). Prevents the
CC       relocation of the sugar-adding enzymes from the Golgi to the
CC       endoplasmic reticulum, thereby restricting the production of sugar-
CC       coated proteins (PubMed:24618899). Upon amino-acid starvation, mediates
CC       transitional endoplasmic reticulum site disassembly and inhibition of
CC       secretion (PubMed:21847093). Binds to chromatin leading to MAPK15
CC       activation and interaction with PCNA, that which protects genomic
CC       integrity by inhibiting MDM2-mediated degradation of PCNA
CC       (PubMed:20733054). Regulates DA transporter (DAT) activity and protein
CC       expression via activation of RhoA (PubMed:28842414). In response to
CC       H(2)O(2) treatment phosphorylates ELAVL1, thus preventing it from
CC       binding to the PDCD4 3'UTR and rendering the PDCD4 mRNA accessible to
CC       miR-21 and leading to its degradation and loss of protein expression
CC       (PubMed:26595526). Also functions in a kinase activity-independent
CC       manner as a negative regulator of growth (By similarity).
CC       Phosphorylates in vitro FOS and MBP (PubMed:11875070, PubMed:16484222,
CC       PubMed:20638370, PubMed:19166846). During oocyte maturation, plays a
CC       key role in the microtubule organization and meiotic cell cycle
CC       progression in oocytes, fertilized eggs, and early embryos (By
CC       similarity). Interacts with ESRRA promoting its re-localization from
CC       the nucleus to the cytoplasm and then prevents its transcriptional
CC       activity (PubMed:21190936). {ECO:0000250|UniProtKB:Q80Y86,
CC       ECO:0000250|UniProtKB:Q9Z2A6, ECO:0000269|PubMed:11875070,
CC       ECO:0000269|PubMed:16484222, ECO:0000269|PubMed:19166846,
CC       ECO:0000269|PubMed:20638370, ECO:0000269|PubMed:20733054,
CC       ECO:0000269|PubMed:21190936, ECO:0000269|PubMed:21847093,
CC       ECO:0000269|PubMed:22948227, ECO:0000269|PubMed:24618899,
CC       ECO:0000269|PubMed:26595526, ECO:0000269|PubMed:28842414,
CC       ECO:0000269|PubMed:29021280}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24;
CC   -!- ACTIVITY REGULATION: Activated by threonine and tyrosine
CC       phosphorylation (PubMed:11875070, PubMed:16336213, PubMed:19166846).
CC       Inhibited by dual specificity phosphatases, such as DUSP1 (By
CC       similarity). Phosphorylation and activation in response to DNA damaging
CC       agents, serum stimulation (PubMed:11875070, PubMed:16336213,
CC       PubMed:19166846). Constitutively activated when phosphorylated on Tyr-
CC       177. Activity depends on the relative rates of MAPK15
CC       autophosphorylation and dephosphorylation by PTPN1 (PubMed:16336213).
CC       {ECO:0000250|UniProtKB:Q9Z2A6, ECO:0000269|PubMed:11875070,
CC       ECO:0000269|PubMed:16336213, ECO:0000269|PubMed:19166846}.
CC   -!- SUBUNIT: Interacts with CSK/c-Src, ABL1, RET and TGFB1I1
CC       (PubMed:11875070, PubMed:16484222, PubMed:16624805). Interacts with
CC       GABARAP, MAP1LC3B and GABARAPL1; controls, in a kinase-dependent
CC       fashion, both basal and starvation-induced autophagy (PubMed:22948227).
CC       Interacts with ESRRA; promotes re-localization of ESRRA to the
CC       cytoplasm through a XPO1-dependent mechanism then inhibits ESRRA
CC       transcriptional activity (PubMed:21190936). Interacts with PCNA; the
CC       interaction is chromatin binding- and kinase activity-dependent and
CC       prevents MDM2-mediated PCNA destruction by inhibiting the association
CC       of PCNA with MDM2 (PubMed:20733054). Interacts with DVL2 (By
CC       similarity). Interacts with CLIC3; MAPK15 does not phosphorylates CLIC3
CC       (By similarity). {ECO:0000250|UniProtKB:Q80Y86,
CC       ECO:0000250|UniProtKB:Q9Z2A6, ECO:0000269|PubMed:11875070,
CC       ECO:0000269|PubMed:16484222, ECO:0000269|PubMed:16624805,
CC       ECO:0000269|PubMed:20733054, ECO:0000269|PubMed:21190936,
CC       ECO:0000269|PubMed:22948227}.
CC   -!- INTERACTION:
CC       Q8TD08; P24941: CDK2; NbExp=4; IntAct=EBI-1383794, EBI-375096;
CC       Q8TD08; P08238: HSP90AB1; NbExp=2; IntAct=EBI-1383794, EBI-352572;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, cilium basal body
CC       {ECO:0000269|PubMed:29021280}. Cell junction, tight junction
CC       {ECO:0000269|PubMed:29021280}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome, centriole {ECO:0000269|PubMed:29021280}.
CC       Cytoplasmic vesicle, autophagosome {ECO:0000269|PubMed:22948227}. Golgi
CC       apparatus {ECO:0000269|PubMed:24618899}. Nucleus
CC       {ECO:0000269|PubMed:20638370, ECO:0000269|PubMed:21190936}. Cytoplasm
CC       {ECO:0000269|PubMed:20638370, ECO:0000269|PubMed:21190936}. Cytoplasm,
CC       cytoskeleton, spindle {ECO:0000250|UniProtKB:Q80Y86}. Note=Co-localizes
CC       to the cytoplasm only in presence of ESRRA (PubMed:21190936).
CC       Translocates to the nucleus upon activation (PubMed:20638370). At
CC       prometaphase I, metaphase I (MI), anaphase I, telophase I, and
CC       metaphase II (MII) stages, is stably detected at the spindle (By
CC       similarity). {ECO:0000250|UniProtKB:Q80Y86,
CC       ECO:0000269|PubMed:20638370, ECO:0000269|PubMed:21190936}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8TD08-1; Sequence=Displayed;
CC       Name=2; Synonyms=Erk8 delta;
CC         IsoId=Q8TD08-2; Sequence=VSP_017919, VSP_017920;
CC       Name=3;
CC         IsoId=Q8TD08-3; Sequence=VSP_017918, VSP_017921;
CC   -!- TISSUE SPECIFICITY: Widely expressed with a maximal expression in lung
CC       and kidney. {ECO:0000269|PubMed:11875070, ECO:0000269|PubMed:16484222}.
CC   -!- DOMAIN: The N-terminal region (1-20) is the minimal region necessary
CC       for ubiquitination and further proteasomal degradation. {ECO:0000250}.
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Autophosphorylated on Thr-175 and Tyr-177; activates the enzyme.
CC       {ECO:0000269|PubMed:11875070, ECO:0000269|PubMed:16336213,
CC       ECO:0000269|PubMed:19166846}.
CC   -!- PTM: Ubiquitinated (PubMed:19166846). Ubiquitination may allow its
CC       tight kinase activity regulation and rapid turnover. May be
CC       ubiquitinated by a SCF E3 ligase (By similarity).
CC       {ECO:0000250|UniProtKB:Q9Z2A6, ECO:0000269|PubMed:19166846}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Appears not to be a CSK- and RET-dependent
CC       activated kinase. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY065978; AAL40897.1; -; mRNA.
DR   EMBL; AY994058; AAY44299.1; -; mRNA.
DR   EMBL; BC028034; AAH28034.1; -; mRNA.
DR   CCDS; CCDS6409.2; -. [Q8TD08-1]
DR   RefSeq; NP_620590.2; NM_139021.2. [Q8TD08-1]
DR   AlphaFoldDB; Q8TD08; -.
DR   SMR; Q8TD08; -.
DR   BioGRID; 128827; 30.
DR   IntAct; Q8TD08; 39.
DR   STRING; 9606.ENSP00000337691; -.
DR   BindingDB; Q8TD08; -.
DR   ChEMBL; CHEMBL5198; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB01017; Minocycline.
DR   DrugCentral; Q8TD08; -.
DR   GuidetoPHARMACOLOGY; 2090; -.
DR   iPTMnet; Q8TD08; -.
DR   PhosphoSitePlus; Q8TD08; -.
DR   BioMuta; MAPK15; -.
DR   DMDM; 74760462; -.
DR   EPD; Q8TD08; -.
DR   jPOST; Q8TD08; -.
DR   MassIVE; Q8TD08; -.
DR   MaxQB; Q8TD08; -.
DR   PaxDb; Q8TD08; -.
DR   PeptideAtlas; Q8TD08; -.
DR   PRIDE; Q8TD08; -.
DR   ProteomicsDB; 74209; -. [Q8TD08-1]
DR   ProteomicsDB; 74210; -. [Q8TD08-2]
DR   ProteomicsDB; 74211; -. [Q8TD08-3]
DR   Antibodypedia; 957; 353 antibodies from 30 providers.
DR   DNASU; 225689; -.
DR   Ensembl; ENST00000338033.9; ENSP00000337691.4; ENSG00000181085.15. [Q8TD08-1]
DR   Ensembl; ENST00000395107.8; ENSP00000378539.4; ENSG00000181085.15. [Q8TD08-3]
DR   Ensembl; ENST00000395108.2; ENSP00000378540.2; ENSG00000181085.15. [Q8TD08-2]
DR   Ensembl; ENST00000615253.4; ENSP00000483093.1; ENSG00000274205.4. [Q8TD08-1]
DR   GeneID; 225689; -.
DR   KEGG; hsa:225689; -.
DR   MANE-Select; ENST00000338033.9; ENSP00000337691.4; NM_139021.3; NP_620590.2.
DR   UCSC; uc003yzj.4; human. [Q8TD08-1]
DR   CTD; 225689; -.
DR   DisGeNET; 225689; -.
DR   GeneCards; MAPK15; -.
DR   HGNC; HGNC:24667; MAPK15.
DR   HPA; ENSG00000181085; Tissue enhanced (choroid plexus, fallopian tube).
DR   MIM; 618616; gene.
DR   neXtProt; NX_Q8TD08; -.
DR   OpenTargets; ENSG00000181085; -.
DR   PharmGKB; PA142671478; -.
DR   VEuPathDB; HostDB:ENSG00000181085; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   GeneTree; ENSGT00940000159758; -.
DR   HOGENOM; CLU_000288_181_14_1; -.
DR   InParanoid; Q8TD08; -.
DR   OMA; PDQEWTR; -.
DR   OrthoDB; 741207at2759; -.
DR   PhylomeDB; Q8TD08; -.
DR   TreeFam; TF105101; -.
DR   PathwayCommons; Q8TD08; -.
DR   SignaLink; Q8TD08; -.
DR   SIGNOR; Q8TD08; -.
DR   BioGRID-ORCS; 225689; 30 hits in 1112 CRISPR screens.
DR   GeneWiki; MAPK15; -.
DR   GenomeRNAi; 225689; -.
DR   Pharos; Q8TD08; Tchem.
DR   PRO; PR:Q8TD08; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q8TD08; protein.
DR   Bgee; ENSG00000181085; Expressed in right uterine tube and 88 other tissues.
DR   Genevisible; Q8TD08; HS.
DR   GO; GO:0005776; C:autophagosome; IDA:UniProtKB.
DR   GO; GO:0005923; C:bicellular tight junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0072687; C:meiotic spindle; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; IDA:UniProtKB.
DR   GO; GO:0004707; F:MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; NAS:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0090494; P:dopamine uptake; IDA:UniProtKB.
DR   GO; GO:0007029; P:endoplasmic reticulum organization; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:1905188; P:positive regulation of metaphase/anaphase transition of meiosis I; IEA:Ensembl.
DR   GO; GO:1905832; P:positive regulation of spindle assembly; IEA:Ensembl.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IDA:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:1904491; P:protein localization to ciliary transition zone; IMP:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; IDA:UniProtKB.
DR   GO; GO:1902017; P:regulation of cilium assembly; IMP:UniProtKB.
DR   GO; GO:0003400; P:regulation of COPII vesicle coating; IMP:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell junction; Cell projection;
KW   Cytoplasm; Cytoplasmic vesicle; Cytoskeleton; Golgi apparatus; Kinase;
KW   Methylation; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   Tight junction; Transferase; Ubl conjugation.
FT   CHAIN           1..544
FT                   /note="Mitogen-activated protein kinase 15"
FT                   /id="PRO_0000232637"
FT   DOMAIN          13..304
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REPEAT          371..375
FT                   /note="PXXXP motif"
FT                   /evidence="ECO:0000305|PubMed:20733054"
FT   REPEAT          378..382
FT                   /note="PXXXP motif"
FT                   /evidence="ECO:0000305|PubMed:20733054"
FT   REPEAT          386..390
FT                   /note="PXXXP motif; regulates binding with chromatin and
FT                   interaction with PCNA"
FT                   /evidence="ECO:0000305|PubMed:20733054"
FT   REPEAT          394..398
FT                   /note="PXXXP motif; regulates binding with chromatin and
FT                   interaction with PCNA"
FT                   /evidence="ECO:0000305|PubMed:20733054"
FT   REGION          265..285
FT                   /note="Necessary to interact with ESRRA, to regulate its
FT                   subcellular localization and to inhibit its transcriptional
FT                   activity"
FT                   /evidence="ECO:0000269|PubMed:21190936"
FT   REGION          300..373
FT                   /note="Requires for interaction with GABARAP, MAP1LC3B AND
FT                   GABARAPL1"
FT                   /evidence="ECO:0000269|PubMed:22948227"
FT   REGION          347..413
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           175..177
FT                   /note="TXY"
FT   ACT_SITE        137
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         19..27
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         42
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         175
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:11875070,
FT                   ECO:0000269|PubMed:16336213, ECO:0000269|PubMed:19166846"
FT   MOD_RES         177
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:11875070,
FT                   ECO:0000269|PubMed:16336213, ECO:0000269|PubMed:19166846"
FT   MOD_RES         449
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   VAR_SEQ         95
FT                   /note="M -> MGCPPSPPPPTAVRTLSA (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_017918"
FT   VAR_SEQ         241..254
FT                   /note="DLLALGSGCRASVL -> GAQTACRSGTGAST (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16484222"
FT                   /id="VSP_017919"
FT   VAR_SEQ         255..544
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16484222"
FT                   /id="VSP_017920"
FT   VAR_SEQ         261..544
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_017921"
FT   VARIANT         221
FT                   /note="T -> K (in dbSNP:rs60732298)"
FT                   /id="VAR_061535"
FT   VARIANT         505
FT                   /note="S -> P (in dbSNP:rs56038219)"
FT                   /id="VAR_061536"
FT   MUTAGEN         42
FT                   /note="K->A: Not phosphorylated at Thr-175 and Tyr-177."
FT                   /evidence="ECO:0000269|PubMed:16336213"
FT   MUTAGEN         42
FT                   /note="K->R: Loss of autophosphorylation and activity. Does
FT                   not increase dopamine transporter activity. Impairs kinase
FT                   activity. Does not rescue cilium assembly in
FT                   MAPK15-depleted cells."
FT                   /evidence="ECO:0000269|PubMed:11875070,
FT                   ECO:0000269|PubMed:28842414, ECO:0000269|PubMed:29021280"
FT   MUTAGEN         59
FT                   /note="R->Q: Does not increase dopamine transporter
FT                   activity. Impairs kinase activity."
FT                   /evidence="ECO:0000269|PubMed:28842414"
FT   MUTAGEN         155
FT                   /note="D->A: Unable to induce the formation of
FT                   autophagosomal structures. Is able to bind to MAP1LC3B and
FT                   to colocalize with this protein to autophagosomal
FT                   structures. Does not induce phosphorylation by methyl
FT                   methanesulfonate. Loas of phosphorylation. Dominant
FT                   negative mutant. Not phosphorylated at Thr-175 and
FT                   Tyr-177."
FT                   /evidence="ECO:0000269|PubMed:16336213,
FT                   ECO:0000269|PubMed:19166846, ECO:0000269|PubMed:22948227"
FT   MUTAGEN         175
FT                   /note="T->A: Loss of autophosphorylation and activity.
FT                   Still heavily phosphorylated at Tyr-177. Does not rescues
FT                   inhibition of O-glycosylation in MAPK15-depleted cells;
FT                   when associated with F-177."
FT                   /evidence="ECO:0000269|PubMed:11875070,
FT                   ECO:0000269|PubMed:16336213, ECO:0000269|PubMed:24618899"
FT   MUTAGEN         177
FT                   /note="Y->A: Loss of autophosphorylation and activity.
FT                   Heavily phosphorylated at Thr-175."
FT                   /evidence="ECO:0000269|PubMed:11875070,
FT                   ECO:0000269|PubMed:16336213"
FT   MUTAGEN         177
FT                   /note="Y->F: Does not rescues inhibition of O-glycosylation
FT                   in MAPK15-depleted cells; when associated with A-175."
FT                   /evidence="ECO:0000269|PubMed:24618899"
FT   MUTAGEN         265..269
FT                   /note="LDALL->ADAAA: Markedly decreases interaction with
FT                   ESRRA. Impairs interaction with ESRRA; when associated with
FT                   A-281 and 284-A--A-285. Loses the ability to re-localize
FT                   ESRRA to the cytoplasm. Does not affect subcellular
FT                   location in cytoplasm in presence of ESRRA. Loses the
FT                   ability to repress ESRRA transcriptional activity."
FT                   /evidence="ECO:0000269|PubMed:21190936"
FT   MUTAGEN         281..285
FT                   /note="LRRLL->ARRAA: Markedly decreases interaction with
FT                   ESRRA. Impairs interaction with ESRRA; when associated with
FT                   A-265 and 268-A--A-269. Loses the ability to re-localize
FT                   ESRRA to the cytoplasm. Does not affect subcellular
FT                   location in cytoplasm in presence of ESRRA.Loses the
FT                   ability to repress ESRRA transcriptional activity."
FT                   /evidence="ECO:0000269|PubMed:21190936"
FT   MUTAGEN         300
FT                   /note="Q->A: Impairs interaction with PCNA. Associates with
FT                   chromatin."
FT                   /evidence="ECO:0000269|PubMed:20733054"
FT   MUTAGEN         340..343
FT                   /note="YQMI->AQMA: Impairs interaction with GABARAP and
FT                   MAP1LC3B. Affects subcellular localization in
FT                   autophagosome. Does not induce autophagy."
FT                   /evidence="ECO:0000269|PubMed:22948227"
FT   MUTAGEN         390
FT                   /note="P->A: Impairs chromatin binding; when associated
FT                   with A-398. Increases kinase activity; when associated with
FT                   A-398."
FT                   /evidence="ECO:0000269|PubMed:20733054"
FT   MUTAGEN         398
FT                   /note="P->A: Impairs chromatin binding; when associated
FT                   with A-390. Increases kinase activity; when associated with
FT                   A-390."
FT                   /evidence="ECO:0000269|PubMed:20733054"
FT   CONFLICT        113
FT                   /note="H -> R (in Ref. 2; AAY44299)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   544 AA;  59832 MW;  758E0E3B9654AAC5 CRC64;
     MCTVVDPRIV RRYLLRRQLG QGAYGIVWKA VDRRTGEVVA IKKIFDAFRD KTDAQRTFRE
     ITLLQEFGDH PNIISLLDVI RAENDRDIYL VFEFMDTDLN AVIRKGGLLQ DVHVRSIFYQ
     LLRATRFLHS GHVVHRDQKP SNVLLDANCT VKLCDFGLAR SLGDLPEGPE DQAVTEYVAT
     RWYRAPEVLL SSHRYTLGVD MWSLGCILGE MLRGRPLFPG TSTLHQLELI LETIPPPSEE
     DLLALGSGCR ASVLHQLGSR PRQTLDALLP PDTSPEALDL LRRLLVFAPD KRLSATQALQ
     HPYVQRFHCP SDEWAREADV RPRAHEGVQL SVPEYRSRVY QMILECGGSS GTSREKGPEG
     VSPSQAHLHK PRADPQLPSR TPVQGPRPRP QSSPGHDPAE HESPRAAKNV PRQNSAPLLQ
     TALLGNGERP PGAKEAPPLT LSLVKPSGRG AAPSLTSQAA AQVANQALIR GDWNRGGGVR
     VASVQQVPPR LPPEARPGRR MFSTSALQGA QGGARALLGG YSQAYGTVCH SALGHLPLLE
     GHHV
//
